ProQR Therapeutics

About ProQR Therapeutics

Het bedrijf richt zich op het verbeteren van de Axiomer™ RNA-editing platformtechnologie. ProQR heeft kantoren in Leiden in Nederland en in Cambridge, Massachusetts, in de Verenigde Staten. Sinds 2021 werkt het bedrijf samen met Eli Lilly and Company aan de ontdekking, ontwikkeling en commercialisering van nieuwe toepassingen met behulp van de Axiomer® technologie. De technologie maakt gebruik van RNA-oligonucleotiden om RNA te veranderen.

This description was written by AI.

Keywords

• Drug Development
• Eye Diseases
• Genetic Diseases
• Inherited Retinal Disease
• Lebers Congenital Amaurosis
• Ophthalmology
• Orphan Drugs
• Pharmaceuticals
• Rare Diseases
• Retinal Degeneration
• Retinal Dystrophy
• Retinitis Pigmentosa
• Rna Editing
• Rna Therapeutics
• Usher Syndrome

Team by function

Based on 193 public job profiles as of 19 September 2026.

• Research / R&D83
• Other / Unclassifiable53
• Operations13
• Executive / C-Suite8
• Finance / Accounting6
• HR / People / Recruiting6
• Legal / Compliance6
• Data / Analytics / Science3
• Healthcare / Medical3
• IT / Infrastructure / Security2
• Marketing2
• Administrative / Office1
• Consulting / Advisory1
• Design / UX1
• Engineering / Software Development1
• Manufacturing / Production1
• Procurement / Supply Chain1
• Product Management1
• Sales1